An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2022 financial results before market open on November 9, 2022. A conference call to discuss these results and recent corporate developments is scheduled for 8:30 am ET on the same day. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, utilizing its next-generation ALLY™ Adaptive Cataract Treatment System. This innovative system integrates proprietary imaging with a dual-pulse femtosecond laser, designed to enhance operational efficiencies in cataract surgeries.
Positive
Announcement of Q3 2022 financial results expected to provide insights into company performance.
The ALLY™ system represents a technological advancement in cataract surgery, potentially improving market position.
Company scheduled a call to engage with investors and discuss strategy.
Negative
None.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, November 9, 2022 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (888) 396 8049 (Domestic) or 416 764 8646 (International). The conference ID number is 51285282. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY™ Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
